Generalized pustular psoriasis (GPP), palmoplantar pustulosis (PPP), and acute generalized exanthematous pustulosis (AGEP) are pustular skin disorders with symptoms including the appearance of pustules and circumscribed collections of fluids and neutrophils within the epidermis. GPP is characterized by sudden and often repeated episodes of high-grade fever and generalized neutrophilic pustules. In contrast, PPP is characterized by chronic localized pustules on the palms and soles, and AGEP is characterized by eruptions occurring classically as adverse drug reactions. Despite different etiologies, these reactions are all characterized by massive influx of neutrophils into the epidermis, and these conditions can be difficult to treat and lifethreatening. [1] [2] [3] GPP has been considered a distinct form of psoriasis associated with IL36RN mutations and, consequently, overstimulation of the IL-36 pathways. 1 The same mutations were detected in patients with PPP and AGEP, leading to speculation that similar molecular alterations might underlie these disorders. 4, 5 Interestingly, gene expression studies on patients with PPP provided evidence that expression of select neural genes was increased, raising the possibility that unique pathways are activated in patients with this disease. 6 However, the molecular abnormalities associated with GPP, PPP, and AGEP have not been systematically compared on a transcriptome-wide level, and common and/or distinct mechanisms driving these inflammatory conditions have remained largely elusive.
To this end, we have performed transcriptional profiling of skin biopsy specimens from patients with GPP/PPP/AGEP and healthy subjects. We report common molecular alterations, including IL36RN, IL8, and other genes affecting neutrophil chemoattraction, as well as unique pathways enriched in each disease. A novel shared feature of GPP/PPP/AGEP was found to be upregulation of the 6-transmembrane epithelial antigens of prostate (STEAP) family of proteins, which correlated with overexpression of a panel of proinflammatory cytokines. Both STEAP1 and STEAP4 were required for crosstalk between these cytokines under inflammatory conditions. These findings open up possibilities in targeting the STEAP pathways for the treatment of IL-36-associated pustular skin conditions and other disorders that share similar inflammatory profiles.
METHODS

Patient cohort
Archived formalin-fixed paraffin-embedded (FFPE) cases were identified by a search of the University of Michigan Department of Pathology database. Cases with reported diagnosis of GPP, PPP, and AGEP were identified, and the diagnosis was verified by means of slide review by a board-certified dermatopathologist (PWH) and chart review. Healthy control subjects and patients with chronic plaque psoriasis were identified in our clinic, and biopsy specimens were obtained for formalin fixation and paraffin embedding before processing and analyses. Healthy volunteers were recruited for blood draws for neutrophil isolation after providing written informed consent. All protocols were approved by the Institutional Review Board of the University of Michigan, Ann Arbor, and the study was carried out in accordance with the Declaration of Helsinki principles.
Microarray
RNA extraction was performed with an E.Z.N.A. FFPE RNA Isolation Kit (Omega Bio-tek, Norcross, Ga) by using the xylene-based extraction method, as specified by the manufacturer, and five 20-mm-thick FFPE biopsy sections. RNA was eluted into water and stored at 2808C until analyzed. Affymetrix Human Gene ST 2.1 microarrays (Affymetrix, Santa Clara, Calif) were processed at the University of Michigan Microarray Core Facility, according to the manufacturer's protocol. The raw microarray data (.CEL files) were processed in the publicly available software R (www.r-project.org) by using a modified version of the ''affy'' package and Human Entrez Gene custom CDF annotation version 19 (http://brainarray.mbni.med.umich.edu/Brainarra/ Database/CustomCDF/genomic_curated_CDF.asp) 7 and the robust multichip average method. 8 Posthybridization quality control checks were performed by using the RNA degradation score, relative log expression, and normalized unscaled standard errors. Data were batch corrected by using an implementation of ComBat v3 9 within the GenePattern pipeline (http://www.GenePattern. org). To remove background, we calculated the median values of all probe sets and removed those probes with expression values of less than the lowest median value 1 1 SD by using a custom Perl script. Gene list comparisons, generation of Venn diagrams, and enrichment of transcription factor motifs were performed on the adjusted expression data in Genomatix (www. genomatix.de) by using the default settings. 10 Biological processes linked to genes commonly altered in patients with the 3 disorders were generated by using GeneGO with DEGs common to GPP, PPP, and AGEP as input and default settings.
K-means clustering was performed with GENE-E (www.broadinstitute. org/cancer/software/GENE-E/). For K-means clustering, gene clustering was performed with default cluster numbers of 2 to 4. For each number of clustering, STEAP1 and STEAP4 coclustered with CXCL1, CXCL8, IL-1, and IL-36 family proteins (Fig 1 and Fig 1. The clustering was also reiterated 20 times, and each time the above the conclusion was validated, suggesting the robustness of the method (data not shown). Functional enrichment analyses and pathway generation were performed with Genomatix, Ingenuity IPA (www.qiagen.com/ingenuity), and ClueGO. 10, 11 For correlation analyses, expression values (normalized relative expression from microarray analyses) were fitted by using linear regression, and slope was tested for significant deviation from 0 (shown as P values). The correlation coefficients for the pairwise comparisons are shown by using r analysis (Pearson correlation coefficients).
Statistics
Statistical analyses of the microarrays were performed by using the significance analysis of microarrays method implemented in the MultiExperiment Viewer application. 12 Mann-Whitney and Student t tests were used in gene expression comparisons, as specified in the figure legends. For Fig 2, STEAP mRNA levels were normalized to those of RPLP0 in each sample. Each data point represents the sample from 1 subject. Lines show the mean of the different samples in the specified group. Plaque psoriasis and PPP samples were compared with NN samples. GPP samples were compared with normal palm and sole skin specimens from 10 healthy subjects. In Fig 3 and Keratinocyte culture, cytokine stimulations, inhibitors, RNA interference, and gene expression analyses Normal human keratinocytes were established from healthy adults, as previously described, 13 and grown in medium 154 CF (Thermo Fisher M154CF500; Thermo Fisher, Waltham, Mass) with human keratinocyte growth supplement (Thermo Fisher S0015). Inhibitors used included the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor PD98059 (Tocris 1213; Tocris Bioscience, Ellisville, Mo), the MEK5 inhibitor Bix02189 
Neutrophil chemotaxis
Primary human neutrophils isolated from peripheral blood were directly used for chemotaxis toward keratinocyte-conditioned medium. To collect the conditioned medium, small interfering RNA was introduced into keratinocytes, and keratinocytes were stimulated with the indicated cytokines. Conditioned medium from stimulated keratinocytes was used as a chemoattractant for neutrophils. Chemotaxis assays were performed with 6.5-mm transwells with 3-mm pores (Corning Laboratories, Corning, NY). Freshly isolated neutrophils (2 3 10 4 ) were plated on the top well of each transwell, and the number of neutrophils migrated to the bottom wells was counted after incubation at 378C for 1 hour.
Hematoxylin and eosin and immunostaining
For hematoxylin and eosin staining, slides were deparaffinized and stained with hematoxylin (1:10 diluted) for 2 minutes, rinsed in running tap water for 5 minutes, stained with eosin for 2 minutes, rinsed with water, dehydrated, and mounted for microscopy. For immunohistochemistry, FFPE human skin biopsy specimens on slides were heated for 30 minutes at 558C, rehydrated, epitope retrieved, blocked, and incubated with primary antibody overnight at 48C. Slides were washed, incubated with secondary antibody, developed with 3,39-diaminobenzidene, and counterstained with hematoxylin for immunohistochemistry or DNA stained with 49-6-diamidino-2-phenylindole dihydrochloride for immunofluorescence. Antibodies were anti-STEAP1 (LS-B1260; LifeSpan BioSciences, Seattle, Wash), anti-IL-36G (sc-80056; Santa Cruz Biotechnology, Dallas, Tex), and anti-STEAP4 (11994-1-AP; Proteintech, Rosemont, Ill).
RESULTS
Transcriptional profiling of patients with GPP, PPP, and AGEP
To characterize the transcriptomic profiles in patients with these pustular skin disorders, we performed microarrays on archived paraffin-embedded skin tissues (FFPE samples) obtained from 30 patients with GPP, 17 patients with PPP, 14 patients with AGEP, and 20 healthy subjects used as control subjects. We also included normal palm and sole skin specimens from 10 healthy subjects used as control subjects for patients with PPP. Histology staining confirmed the presence of intraepidermal A, Quantitative RT-PCR of STEAP1 to STEAP4 mRNA levels in skin of patients with plaque psoriasis (PP), healthy control subjects (NN), patients with PPP, normal palm and sole skin specimens from 10 healthy subjects (NNN), and patients with GPP. Mann-Whitney test: *P < .05 and **P < .01. B, Immunohistochemistry of STEAP1 and STEAP4 in skin of patients with GPP. C and D, Immunofluorescence costaining of STEAP1 (Fig 2, C) or STEAP4 (Fig 2, D) and IL-36g in skin of healthy control subjects (NN) and patients with GPP. pustules (Fig 1, A) . In addition, we compared our PPP results with published transcriptomic profiles obtained from fresh tissues. 6 The majority of genes altered in patients with PPP (82% of PPP-increased genes and 76% of PPP-decreased genes) were confirmed by our study (see Fig E1 in this article's Online Repository at www.jacionline.org). As negative controls, the same number of randomly selected genes did not show consistent upregulation or downregulation in patients with PPP (see Fig  E1) . Collectively, reported PPP-increased genes exhibited significantly higher expression in samples from patients with PPP versus those from control subjects from our data set (P 5 .0158, see Fig E1) , and reported PPP-decreased genes showed decreased expression in our PPP samples (P 5 .0002, see Fig E1) .
From our microarray experiments, skin of patients with GPP exhibited the most altered genes, with a total of 2151 differentially expressed genes (DEGs) identified compared with normal skin (false discovery rate < 0.05). Similarly, 461 DEGs were identified in skin of patients with PPP, and 197 DEGs were identified in skin of patients with AGEP (Fig 1, B) . Patients with GPP showed the most unique mRNA profile, with 83.5% of DEGs (1797/2151) being GPP specific compared with 42.3% for patients with PPP and 0.5% for patients with AGEP. The top GPPspecific biological pathway enriched was protein ubiquitination, which is known to be dysregulated in patients with inflammatory and autoimmune diseases (Fig 1, B) .
15
It is also worth noting that we detected significant enrichment of the caspase signaling pathway in GPP-specific genes (P 5 7.31 3 10 25 , 39 genes), including caspase-1, caspase-4, and caspase-11, which mediate inflammatory responses. 16, 17 Caspase-1 activates IL-1b, an additional GPP-specific DEG, as part of an activated inflammasome. Importantly, autoinflammatory disorders, such as Muckle-Wells syndrome, familial cold autoinflammatory syndrome, and chronic infantile neurological cutaneous and articular syndrome, which share the periodic fever and systemic skin inflammation symptoms with GPP, are triggered by a hyperactivated inflammasome involving excessive caspase-1 activity and overproduction of IL-1b. 18 These GPPspecific DEGs together with the extensive attribute of gene expression alterations might contribute to the systematic and severe features associated with GPP symptoms.
PPP-specific genes showed major enrichment in T-cell functions (Fig 1, B) . In addition, consistent with localized lesions on the palms and soles, we detected BBS1 as a PPP-only gene, mutation of which underlies human limb malformation, specifically abnormalities of the hands and feet. 19, 20 We also observed enrichment of genes known to link with Twist1 (P 5 5.31 3 10 23 , 7 genes), a crucial player in limb formation and patterning, 21, 22 in the PPP-specific gene set only. Promoters of PPP-specific genes were significantly enriched with binding motifs for the Twist1 family of transcription factors (z score 5 11.95, see Fig E2 in this article's Online Repository at www.jacionline.org). The interactions between these limb genes and inflammatory pathways could serve as one possible explanation for the localized PPP lesions on hands and feet.
Common processes enriched in patients with GPP/PPP/AGEP included IL-17A signaling and granulocyte adhesion and diapedesis, which is consistent with a shared inflammation phenotype involving neutrophil infiltration (Fig 1, B) .
23,24
STEAP expression is increased in patients with pustular skin disorders STEAP4 was one of the genes commonly altered in all 3 disease phenotypes (GPP, PPP, and AGEP) from the microarray analyses, with a potential function in defense response (Fig 1, C) . Thus we decided to focus our subsequent studies on this family of proteins with the attempt to delineate a novel inflammatory pathway. The STEAP family of proteins are comprised of STEAP1 to STEAP4 and share metalloreductase activities. STEAP1 and STEAP2 are overexpressed in patients with various types of cancers, and the cellular functions of STEAP1 to STEAP4 have been linked to molecular trafficking, cell proliferation, and death. 25, 26 From quantitative RT-PCR analyses, STEAP1 and STEAP4 levels were increased in patients with PPP/GPP but not in those with plaque psoriasis (Fig 2, A) . By contrast, expression of STEAP2 and STEAP3 was not increased in patients with PPP, GPP, or plaque psoriasis. Immunostaining of STEAP1 and STEAP4 revealed their epithelial localization in normal skin and concentrations in or around neutrophil infiltration of the epidermis in a manner that partially overlaps with IL-36g (Fig 2, B and C) . We also examined mRNA levels in various cell types, including keratinocytes, fibroblasts, T cells, B cells, monocytes, macrophages, and dendritic cells (see Fig E3 in this article' s Online Repository at www.jacionline.org). STEAP4, increases in which were identified in patients with GPP, PPP, and AGEP in microarray analyses (Fig 1, C) , was expressed to the highest degree in keratinocytes. In addition, only in keratinocytes were both STEAP1 and STEAP4 expressed at relatively high levels. Therefore we focused our subsequent analyses on keratinocytes.
STEAP1 and STEAP4 cocluster with a group of inflammatory cytokines, including IL-1, IL-36, and CXCL1/8
To investigate cytokine activities in patients with GPP, PPP, and AGEP, we performed clustering based on changes in expression of various cytokines (interleukins, interferons, CCLs, CXCLs, and TNF) and their related genes (receptors and induced genes). This led to the separation of cytokines into 4 distinct groups (groups A-D), and patients were subsequently stratified into 3 groups (subgroups 1-3) based on their distinct patterns of cytokine profiles (Fig 3) . IL-1A/B, IL-36A/B/G/RN, and the neutrophil chemokines CXCL1 and CXCL8 were found to be clustered together with STEAP1 and STEAP4. This grouping of STEAP1/4 with neutrophil activators was a prominent feature of the patients in group 3 possibly related to a more severe subcategory of disease (Fig 3) , and their expression levels correlated positively with expression levels of IL1A, IL1B, IL36A, IL36G, CXCL1, and IL8 in all samples (GPP/PPP/AGEP/NN, Fig 4) and were most prominent in patients with the most robust inflammatory phenotype (subgroup 3, see Fig E4 in this article's Online Repository at www.jacionline.org), suggesting that the STEAP proteins function in the same pathway as IL-1, IL-36, and the neutrophil chemokines CXCL1 and IL-8.
For both patients with GPP and those with PPP, patients in subgroup 3 exhibited significantly enriched expression of cellcycle checkpoint genes compared with patients in subgroup 2. For both patients with GPP and those with AGEP, there was significantly increased expression of inflammatory genes, including Toll-like receptor (TLR) and CCL2 pathways, when comparing patients in subgroup 3 with those in subgroup 2 (see Fig E5 in this article' s Online Repository at www.jacionline.org). Thus in patients with the pustular skin disorders analyzed, stronger expression of the neutrophil activators correlated with dysregulated cell-cycle checkpoints and a more robust inflammatory profile.
Despite the enrichment of common molecular pathways across patients with GPP, PPP, and AGEP, these patients showed limited overlap in terms of the specific genes altered (see Fig E6 in this article's Online Repository at www.jacionline.org). Focusing on the checkpoint pathway that was highlighted in both patients with GPP and those with PPP, 19 DEGs in the pathways were common to both diseases. Twenty-four DEGs were PPP specific, and 16 were GPP specific (see Fig E6) . This indicates that a shared cytokine profile resulted in disease-specific gene expression changes, although they converged into similar manifestations on a higher order (eg, checkpoint regulation).
STEAP4 expression is induced by proinflammatory cytokines
To investigate a potential role of STEAP1 and STEAP4 in cytokine responses, we first examined whether STEAP expression could be induced by inflammatory cytokines. In primary human keratinocytes STEAP4 expression was induced by TNFa, IL-1b, IL-36a, IL-36g, IL-17A, and IL-17A combined with TNF-a or IL-22. By contrast, STEAP1 expression was not induced by these cytokine stimulations (Fig 5, A and B) . We then analyzed the signaling pathways regulating STEAP expression by using inhibitors of MEK1/2, MEK5, and the nuclear factor kB pathway, respectively (Fig 5, C-L) . The MEK1/2 inhibitor PD98059 inhibited STEAP1 expression both in baseline conditions and under IL-1b stimulation (Fig 5, C and F) . However, the requirement for MEK1/2 activity was diminished under TNF-a and IL-17A treatment, indicating altered regulatory mechanisms (Fig 5, D and E) . By contrast, STEAP4 remained sensitive to (Fig 5, A) and STEAP4 (Fig 5, B) by using quantitative RT-PCR in untreated and cytokine-treated keratinocytes. C-L, Relative expression of STEAP1 (Fig 5, C-G) and STEAP4 (Fig 5, H-L) by using quantitative RT-PCR under various conditions (no cytokines, TNF-a stimulation, IL-17A stimulation, IL-1b stimulation, or IL-36a stimulation) with or without inhibitor cotreatment. *P < .05, Student t test. (Fig 5, H-L) . In the GPP/PPP/AGEP/NN skin biopsy specimens, expression of the MEK1/2 targets FOSL1, HIF1A, and CRABP2 positively correlated with STEAP4 expression (see Fig E7 in this article' s Online Repository at www.jacionline.org), 27 supporting the possibility that MEK1/2 and STEAP4 function in the same pathway in vivo. The MEK5 inhibitor Bix02189 and the IkBa phosphorylation inhibitor Bay 11-7085 also had a greater effect on STEAP4 expression compared with STEAP1, suggesting STEAP4 expression is more susceptible to complex regulation by several cell-signaling pathways.
MEK1/2 inhibition under all conditions tested
STEAPs are required for optimal cytokine response and neutrophil chemotaxis
We analyzed the roles of STEAP1 and STEAP4 in mediating cytokine response by repressing STEAP expression in primary human keratinocytes (see Fig E8 in this article' s Online Repository at www.jacionline.org). We focused on induced expression of IL1A, IL1B, IL36A, IL36G, CXCL1, and IL8 because this group of cytokines coclustered with STEAP1 and STEAP4 in patients with GPP/PPP/AGEP (Fig 3) . STEAP1 RNA interference resulted in impaired induction of proinflammatory cytokines: induction of IL1A and IL1B by TNF-a and IL-1b; induction of IL36G by TNF-a, IL-1b, and IL-36a; induction of CXCL1 by IL36-a, IL-17A, and IL-22; and induction of CXCL8 by IL-1b and IL-36a were all weakened (Fig 6 and see Figs E8-E12 in this article's Online Repository at www. jacionline.org). STEAP4 RNA interference resulted in impaired induction of IL1A by TNF-a; induction of IL36G by TNF-a and IL-36a; induction of CXCL1 by IL-36a, IL-17A, and IL-22; and induction of CXCL8 by IL-1b (Fig 6 and see Figs E10 and E11). The pattern of STEAP1 and STEAP4 function was found to be similar, although STEAP1 knockdown resulted in broader suppression (see Fig E13 in this article' s Online Repository at www.jacionline.org). IL1A (A and D) , IL1B (B and E), IL36G (C, F, and H), CXCL1 (I, K, and L), and CXCL8 (G and J). *P < .05 and (*)P < .1, Student t test.
We then tested whether the STEAP proteins regulate neutrophil chemotaxis toward the inflammatory environment conditioned by keratinocytes. We knocked down STEAP1 or STEAP4 in primary keratinocytes and stimulated keratinocytes with IL36-a or IL-1b, which we had previously found to induce CXCL1/8 in a STEAPdependent manner (Fig 6) . We then collected conditioned medium from the stimulated keratinocytes and analyzed its ability to attract primary neutrophils by transwell assays. We found that conditioned medium from STEAP-reduced keratinocytes was less efficient in inducing neutrophil migration compared with that from wild-type keratinocytes (Fig 7) .
Collectively, these data suggest that STEAPs are required for the maximal induction of proinflammatory neutrophil-attracting and neutrophil-activating cytokines, as well as neutrophil chemotaxis, contributing to the shaping of inflammatory environments in various neutrophil-driven inflammatory responses.
DISCUSSION
We performed transcriptional profiling of patients with GPP, PPP, and AGEP from FFPE tissues. Quantitative gene expression studies from FFPE tissues can be complicated by limitations, including nucleic acid integrity and amplification efficiency. 28 Comparison of our results with those of published PPP studies from fresh tissue has revealed 70% to 80% overlap (see Fig  E1) . Therefore profiling from FFPE clinical tissue samples remains a valuable method for analysis of archived specimens.
We have provided evidence that STEAP1 and STEAP4 are relevant in the inflammatory responses observed in patients with GPP, PPP, and AGEP. In vivo STEAP1 and STEAP4 are upregulated and coexpressed with IL-1, IL-36, CXCL1, CXCL8, and additional proinflammatory cytokines in patients with GPP/ PPP/AGEP, delineating the inflammatory milieu for a subgroup of patients featuring dysregulated checkpoint signaling and excessive activation of inflammatory pathways involving TLRs and CCL2 (Figs 1 and 2 ). STEAP4 is inducible by various stimuli, including IL-1b, IL-36a, IL-36g, IL-17A, and TNF-a, amplifying the inflammatory reactions on top of those supported by STEAP1, expression of which is not cytokine induced (Fig 5) . STEAP1 and STEAP4 are required for optimal induction of IL-1 and IL-36 cytokines, as well as expression of the neutrophil chemokines CXCL1 and IL-8 (Fig 6) . Importantly, keratinocytes deficient in STEAP1/4 become less efficient in inducing neutrophil chemotaxis (Fig 7) . Therefore STEAP1 and STEAP4 support neutrophil-rich proinflammatory responses in the skin, as observed in patients with pustular psoriasis.
In contrast to patients with pustular psoriasis, STEAP1 and STEAP4 are not upregulated in patients with plaque psoriasis (Fig 2) . One important pathologic difference between the 2 conditions is the distinctive appearance of neutrophil-rich pustules in patients with pustular, but not those with plaque, psoriasis. We found that STEAP1 and STEAP4 promote neutrophil chemotaxis toward the keratinocyte-conditioned environment (Fig 7) , possibly through stimulating the production of various neutrophil-acting cytokines, including the IL-36 proteins CXCL1 and CXCL8 (Fig 6 and see Fig E13) . Therefore the distinct neutrophil-activating activities of STEAP1 and STEAP4 might underlie the pathologic alterations in patients with pustular psoriasis but not those with nonpustular psoriasis.
The identified molecular abnormalities might underlie the common pustular phenotypes observed in patients with GPP, PPP, and AGEP. Aberrant IL-36 signaling is thought to drive inflammation in patients with GPP, PPP, and AGEP, 1, 4, 5, [29] [30] [31] and neutrophils play an important role in this pathway for their posttranslational processing and activation of the IL-36 cytokines. 32 IL-8 and CXCL1 are among the most potent chemoattractant molecules for the recruitment of neutrophils. [33] [34] [35] [36] TLR ligation stimulates neutrophil function, and CCL2 has a critical role in neutrophil recruitment. [37] [38] [39] [40] In addition, there is an emerging understanding of the effects of neutrophil activation on cell-cycle checkpoints, such as DNA damage response, G2/ M checkpoint activation, and subsequent replication errors, as well as how their dysregulation and genomic abnormalities produced in these processes might in turn amplify inflammation. [41] [42] [43] [44] The checkpoint pathway proteins overexpressed in the patients with GPP/PPP/AGEP included BUB1B and MAD2L1, overexpression of which has been associated with chromosomal instability. [45] [46] [47] There was also increased CDC6, CCNA1, and CCNB1 expression that might directly promote keratinocyte proliferation and allow for increased inflammatory gene expression mediated by CDK6. 48 The capture of these molecular alterations in our patient data sets has provided formal support for their involvement in human inflammatory diseases.
We have found that the above-mentioned alterations in cytokine responses are functionally linked by STEAP1 and STEAP4. The STEAP proteins were first identified as surface antigens overexpressed in patients with prostate cancer and later found to be overexpressed in patients with many different cancers, such as breast and bladder carcinoma and Ewing sarcoma. 25, 26 They share a 6-transmembrane domain and a C-terminal domain with homology to the F 420 :NADPH-oxidoreductase in archaea and bacteria, as well as a role in ion metabolism, including iron and copper uptake.
26,49-51 STEAP1 and STEAP2 promote cancer cell proliferation and prevent apoptosis, whereas STEAP4 regulates adipocyte differentiation and modulates the effect of TNFa on insulin resistance in mice. [52] [53] [54] [55] However, the function of STEAP4 in human subjects remains unclear, particularly the role of STEAP4 in preadipocyte differentiation. 56 Our studies have established a positive link between human STEAP1 and STEAP4 and proinflammatory cytokines in vivo in several neutrophil-driven disorders. It is not yet known whether the inflammatory activities of STEAPs are in direct causal relationship with their regulation of ion metabolism. In patients with GPP, PPP, and AGEP, we observed significant alterations in genes involved in iron biology, including HEPHL1, LCN2, ALAS1, SOD2, and EROL, concomitant with STEAP upregulation (data not shown). HEPHL1 is a homologue of the ferroxidase hephaestin and can exhibit iron oxidation activity. 57 Regulation of labile iron levels by LCN2 protects mice against sepsis.
58 ALAS1 catalyzes the rate-limiting step in the biosynthesis of heme.
59 SOD2 gains peroxidase activity when bound to iron, generating oxygen radicals. 60 ERO1L expression is induced by iron deficiency. 61 Therefore the role of STEAPs in linking iron metabolism and inflammation would be of interest to address in future studies.
In conclusion, we have delineated transcriptomic changes in patients with 3 pustular skin disorders, GPP, PPP, and AGEP, which converged on neutrophil chemotaxis and diapedesis and cytokines known to drive neutrophil-rich inflammatory processes, including IL-1 and members of the IL-36 family. We identify a novel inflammatory pathway regulated by 2 STEAP proteins, STEAP1 and STEAP4, as positive regulators controlling expression of neutrophil activators in the skin and potential therapeutic targets in patients with neutrophil-driven pustular diseases.
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